Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies-Reference-Cited by-同舟云学术

Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies

Published:2015-11 Issue:16 Volume:51 Page:2368-2374
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Albiges Laurence,Kube Ulrich,Eymard Jean-Christophe,Schmidinger Manuela,Bamias Aristotelis,Kelkouli Nadia,Mraz Bernhard,Florini Styliani,Guderian Gernot,Cattaneo Agnese,Bergmann Lothar

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. National comprehensive cancer network. NCCN clinical practice guidelines in oncology kidney cancer (version 3.2014), 2014. Available at .

2. Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma; UPDATE, 2013.

3. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2014

4. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors;Motzer;Cancer,2010

5. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy;Grunwald;Eur J Cancer,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm;Anti-Cancer Drugs;2022-11-16

2. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma;JCO Precision Oncology;2022-05

3. Targeted Therapy for Renal Cell Carcinoma;Urologic Oncology;2022

4. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers;Clinical Genitourinary Cancer;2021-06

5. Therapeutic Drug Monitoring of Everolimus in Oncology: Evidences and Perspectives;Therapeutic Drug Monitoring;2019-10